{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:04:48Z","timestamp":1772463888795,"version":"3.50.1"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00011-021-01445-2","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T23:58:10Z","timestamp":1613779090000},"page":"389-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection"],"prefix":"10.1007","volume":"70","author":[{"given":"Zahra","family":"Bahari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohreh","family":"Jangravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Ghoshooni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Afarinesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0665-186X","authenticated-orcid":false,"given":"Gholam Hossein","family":"Meftahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"1445_CR1","doi-asserted-by":"crossref","unstructured":"Palanques-Pastor T, L\u00f3pez-Briz E, Andr\u00e9s JLP. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19. Europ J Hosp Pharm. 2020;0:1\u20132.","DOI":"10.1136\/ejhpharm-2020-002322"},{"issue":"7","key":"1445_CR2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S2665-9913(20)30120-X","volume":"2","author":"J Zhong","year":"2020","unstructured":"Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):428\u201336.","journal-title":"Lancet Rheumatol."},{"key":"1445_CR3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cca.2020.06.017","volume":"59","author":"P Song","year":"2020","unstructured":"Song P, Li W, Xie J, Hou Y, You C. Cytokine Storm Induced by SARS-CoV-2. Clin Chim Acta. 2020;59:280\u20137.","journal-title":"Clin Chim Acta."},{"key":"1445_CR4","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","volume":"39","author":"M Soy","year":"2020","unstructured":"Soy M, Keser G, Atag\u00fcnd\u00fcz P, Tabak F, Atag\u00fcnd\u00fcz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39:2085\u201394.","journal-title":"Clin Rheumatol."},{"key":"1445_CR5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocn.2020.05.017","volume":"77","author":"I Ahmad","year":"2020","unstructured":"Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020;77:8\u201312.","journal-title":"J Clin Neurosci."},{"issue":"26","key":"1445_CR6","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1056\/NEJMc2009191","volume":"382","author":"G Toscano","year":"2020","unstructured":"Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D, Baldanti F, Daturi R, Postorino P, Cavallini A. Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574\u20136.","journal-title":"N Engl J Med."},{"issue":"1","key":"1445_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/JAD-200581","volume":"76","author":"M Fotuhi","year":"2020","unstructured":"Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimers Dis. 2020;76(1):3\u201319.","journal-title":"J Alzheimers Dis."},{"key":"1445_CR8","doi-asserted-by":"publisher","unstructured":"Garcia MA, Barreras PV, Lewis A, Pinilla G, Sokoll LJ, Kickler T, Mostafa H, Caturegli M, Moghekar A, Fitzgerald KC, Neuro-COVID H. Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation. medRxiv. Preprint. 2021. doi: https:\/\/doi.org\/10.1101\/2021.01.10.20249014","DOI":"10.1101\/2021.01.10.20249014"},{"issue":"1","key":"1445_CR9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12974-020-01957-4","volume":"17","author":"A Jarrahi","year":"2020","unstructured":"Jarrahi A, Ahluwalia M, Khodadadi H, Salles ED, Kolhe R, Hess DC, Vale F, Kumar M, Baban B, Vaibhav K, Dhandapani KM. Neurological consequences of COVID-19: What have we learned and where do we go from here? J Neuroinflammation. 2020;17(1):286.","journal-title":"J Neuroinflammation."},{"key":"1445_CR10","doi-asserted-by":"crossref","first-page":"108448","DOI":"10.1016\/j.clim.2020.108448","volume":"215","author":"S Felsenstein","year":"2020","unstructured":"Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448.","journal-title":"Clin Immunol."},{"issue":"1","key":"1445_CR11","first-page":"3","volume":"36","author":"OM Lucherini","year":"2018","unstructured":"Lucherini OM, Rigante D, Sota J, Fabiani C, Obici L, Cattalini M, et al. Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases. Clin Exp Rheumatol. 2018;36(1):3\u20139.","journal-title":"Clin Exp Rheumatol."},{"key":"1445_CR12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3389\/fimmu.2019.01745","volume":"10","author":"O Schnappauf","year":"2019","unstructured":"Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The pyrin inflammasome in health and disease. Front Immunol. 2019;10:1745.","journal-title":"Front Immunol."},{"issue":"1","key":"1445_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-0191-1","volume":"5","author":"M Catanzaro","year":"2020","unstructured":"Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):1\u201310.","journal-title":"Signal Transduct Target Ther."},{"key":"1445_CR14","doi-asserted-by":"crossref","unstructured":"Kumar S, Nyodu R, Maurya VK, Saxena SK. Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection. In Coronavirus Disease 2019 (COVID-19) 2020;43\u201353.","DOI":"10.1007\/978-981-15-4814-7_5"},{"issue":"2","key":"1445_CR15","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/JVI.01782-06","volume":"81","author":"SA Kopecky-Bromberg","year":"2007","unstructured":"Kopecky-Bromberg SA, Mart\u00ednez-Sobrido L, Frieman M, Baric RA, Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81(2):548\u201357.","journal-title":"J Virol."},{"key":"1445_CR16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00011-020-01372-8","volume":"69","author":"GH Meftahi","year":"2020","unstructured":"Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of \u201cinflame-aging.\u201d Inflamm Res. 2020;69:825\u201339.","journal-title":"Inflamm Res."},{"issue":"1","key":"1445_CR17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15407\/ubj93.01.018","volume":"93","author":"GH Meftahi","year":"2021","unstructured":"Meftahi GH, Bahari Z, Jangravi Z, Iman M. A vicious circle between oxidative stress and cytokine storm in ARDS pathogenesis during COVID-19 infection. Ukr Biochem J. 2021;93(1):19\u201329.","journal-title":"Ukr Biochem J."},{"issue":"19","key":"1445_CR18","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.lfs.2005.09.038","volume":"78","author":"X Xudong","year":"2006","unstructured":"Xudong X, Junzhu C, Xingxiang W, Furong Z, Yanrong L. Age-and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166\u201371.","journal-title":"Life Sci."},{"issue":"7","key":"1445_CR19","doi-asserted-by":"crossref","first-page":"e13168","DOI":"10.1111\/acel.13168","volume":"19","author":"J Chen","year":"2020","unstructured":"Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W. Individual variation of the SARS-CoV2 receptor ACE2 gene expression and regulation. Aging Cell. 2020;19(7):e13168.","journal-title":"Aging Cell"},{"key":"1445_CR20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41430-020-0661-0","volume":"74","author":"M Ebadi","year":"2020","unstructured":"Ebadi M, Montano-Loza AJ. Perspective: improving vitamin D status in the management of COVID-19. Eur J Clin Nutr. 2020;74:856\u20139.","journal-title":"Eur J Clin Nutr."},{"issue":"5","key":"1445_CR21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","volume":"20","author":"X Cao","year":"2020","unstructured":"Cao X. COVID-19: immunopathology and its implications for therapy. Nature Rev Immunol. 2020;20(5):269\u201370.","journal-title":"Nature Rev Immunol."},{"issue":"8","key":"1445_CR22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, Van Der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Rev Drug Dis. 2012;11(8):633\u201352.","journal-title":"Nature Rev Drug Dis."},{"issue":"14","key":"1445_CR23","first-page":"3720","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Am J Hematol. 2011;117(14):3720\u201332.","journal-title":"Am J Hematol."},{"issue":"51","key":"1445_CR24","doi-asserted-by":"crossref","first-page":"20684","DOI":"10.1073\/pnas.1116848108","volume":"108","author":"Y Berda-Haddad","year":"2011","unstructured":"Berda-Haddad Y, Robert S, Salers P, Zekraoui L, Farnarier C, Dinarello CA, et al. Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1\u03b1. Proc Natl Acad Sci USA. 2011;108(51):20684\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"1445_CR25","doi-asserted-by":"crossref","unstructured":"Dinarello C A, Ikejima T, Warner SJ, Orencole SF, Lonnemann, G, Cannon JG, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro.\u00a0J Immunol. 1987;139(6):1902\u20131910.","DOI":"10.4049\/jimmunol.139.6.1902"},{"issue":"105","key":"1445_CR26","first-page":"1","volume":"3","author":"A Weber","year":"2010","unstructured":"Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3(105):1.","journal-title":"Sci Signal."},{"issue":"1","key":"1445_CR27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12031-018-1062-x","volume":"65","author":"H Ahmadi","year":"2018","unstructured":"Ahmadi H, Boroujeni ME, Sadeghi Y, Abdollahifar MA, Khodagholi F, Meftahi GH, et al. Sertoli cells avert neuroinflammation-induced cell death and improve motor function and striatal atrophy in rat model of Huntington disease. J Mol Neurosci. 2018;65(1):17\u201327.","journal-title":"J Mol Neurosci."},{"key":"1445_CR28","doi-asserted-by":"crossref","unstructured":"Efati M, Khorrami M, Jangravi Z, Mahmoudabadi AZ, Raeiszadeh M, Sarshoori JR. HESA-A Attenuates Hepatic Steatosis in NAFLD Rat Model Through the Suppression of SREBP-1c and NF-k\u03b2. Int J Pept Res Ther. 2019;1\u20138.","DOI":"10.1007\/s10989-019-09930-3"},{"issue":"5","key":"1445_CR29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","volume":"39","author":"R Channappanavar","year":"2017","unstructured":"Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529\u201339.","journal-title":"Semin Immunopathol."},{"issue":"5","key":"1445_CR30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"Q Ruan","year":"2020","unstructured":"Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Inten Care Med. 2020;46(5):846\u20138.","journal-title":"China Inten Care Med."},{"issue":"1","key":"1445_CR31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s42358-020-0117-1","volume":"60","author":"A \u015eahin","year":"2020","unstructured":"\u015eahin A, Derin ME, Albayrak F, Karaka\u015f B, Karag\u00f6z Y. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant\/unresponsive familial Mediterranean fever. Adv Rheumatol. 2020;60(1):12.","journal-title":"Adv Rheumatol."},{"issue":"5","key":"1445_CR32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/acr2.11140","volume":"2","author":"TL Muskardin","year":"2020","unstructured":"Muskardin TL. Intravenous Anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019. ACR Open Rheumatol. 2020;2(5):283.","journal-title":"ACR Open Rheumatol."},{"issue":"5","key":"1445_CR33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/acr2.11135","volume":"2","author":"LA Monteagudo","year":"2020","unstructured":"Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol. 2020;2(5):276\u201382.","journal-title":"ACR Open Rheumatol."},{"issue":"2","key":"1445_CR34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","volume":"44","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: re-analysis of a prior Phase III trial. Critical Care Med. 2016;44(2):275.","journal-title":"Critical Care Med."},{"issue":"7","key":"1445_CR35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","volume":"17","author":"J Ram\u00edrez","year":"2018","unstructured":"Ram\u00edrez J. Ca\u00f1ete JD (2018) Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018;17(7):727\u201332.","journal-title":"Expert Opin Drug Saf."},{"key":"1445_CR36","doi-asserted-by":"crossref","unstructured":"Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. 2020;1\u20132.","DOI":"10.1136\/annrheumdis-2020-217706"},{"issue":"6","key":"1445_CR37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2665-9913(20)30127-2","volume":"2","author":"G Cavalli","year":"2020","unstructured":"Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):325\u201331.","journal-title":"Lancet Rheumatol."},{"key":"1445_CR38","doi-asserted-by":"crossref","unstructured":"Yang BB, Gozzi P, Sullivan JT. Pharmacokinetics of anakinra in subjects of heavier vs. lighter body weights. Clin Trans Sci. 2019;12(4):371\u20138.","DOI":"10.1111\/cts.12622"},{"issue":"7","key":"1445_CR39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2665-9913(20)30160-0","volume":"2","author":"A King","year":"2020","unstructured":"King A, Vail A, O\u2019Leary C, Hannan C, Brough D, Patel H, et al. Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatol. 2020;2(7):379\u201381.","journal-title":"Lancet Rheumatol."},{"key":"1445_CR40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijid.2020.05.026","volume":"96","author":"G Filocamo","year":"2020","unstructured":"Filocamo G, Mangioni D, Tagliabue P, Aliberti S, Costantino G, Minoia F, et al. Use of anakinra in severe COVID-19: a case report. Internation J Infect Dis. 2020;96:607\u20139.","journal-title":"Internation J Infect Dis."},{"issue":"10229","key":"1445_CR41","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u201362.","journal-title":"Lancet"},{"issue":"8","key":"1445_CR42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2665-9913(20)30167-3","volume":"2","author":"C Ucciferri","year":"2020","unstructured":"Ucciferri C, Auricchio A, Di Nicola M, Potere N, Abbate A, Cipollone F, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020;2(8):457\u20138.","journal-title":"Lancet Rheumatol."},{"key":"1445_CR43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fcvm.2020.00078","volume":"7","author":"L Wang","year":"2020","unstructured":"Wang L, Zhang Y, Zhang S. Cardiovascular impairment in COVID-19: learning from current options for cardiovascular anti-inflammatory therapy. Front Cardiovasc Med. 2020;7:78.","journal-title":"Front Cardiovasc Med."},{"issue":"8","key":"1445_CR44","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"HM Hoffman","year":"2008","unstructured":"Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58(8):2443\u201352.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"1445_CR45","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14397595.2018.1457469","volume":"29","author":"\u00d6 Varan","year":"2019","unstructured":"Varan \u00d6, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol. 2019;29(2):363\u20136.","journal-title":"Mod Rheumatol."},{"issue":"3","key":"1445_CR46","first-page":"138","volume":"34","author":"S Kapur","year":"2009","unstructured":"Kapur S, Bonk ME. Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. Pharm Therap. 2009;34(3):138.","journal-title":"Pharm Therap."},{"issue":"1","key":"1445_CR47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-019-0182-y","volume":"9","author":"S Karkhur","year":"2019","unstructured":"Karkhur S, Hasanreisoglu M, Vigil E, Halim MS, Hassan M, Plaza C, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019;9(1):17.","journal-title":"J Ophthalmic Inflamm Infect."},{"issue":"1","key":"1445_CR48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","volume":"9","author":"H Han","year":"2020","unstructured":"Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123\u201330.","journal-title":"Emerg Microbes Infect."},{"key":"1445_CR49","doi-asserted-by":"crossref","unstructured":"Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020.","DOI":"10.1101\/2020.02.10.20021832"},{"issue":"2","key":"1445_CR50","first-page":"100029","volume":"2","author":"G Magro","year":"2020","unstructured":"Magro G. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the\u2019culprit lesion\u2019of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine. 2020;2(2):100029.","journal-title":"Cytokine"},{"issue":"5","key":"1445_CR51","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954.","journal-title":"Int J Antimicrob Agents."},{"issue":"10","key":"1445_CR52","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/eji.201243018","volume":"43","author":"SN Lauder","year":"2013","unstructured":"Lauder SN, Jones E, Smart K, Bloom A, Williams AS, Hindley JP, et al. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Europ J Immunol. 2013;43(10):2613\u201325.","journal-title":"Europ J Immunol."},{"issue":"4","key":"1445_CR53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jmv.20556","volume":"78","author":"T Okabayashi","year":"2006","unstructured":"Okabayashi T, Kariwa H, Yokota SI, Iki S, Indoh T, Yokosawa N, et al. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol. 2006;78(4):417\u201324.","journal-title":"J Med Virol."},{"key":"1445_CR54","doi-asserted-by":"crossref","unstructured":"Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. MedRxiv. 2020.","DOI":"10.1101\/2020.02.25.20025643"},{"issue":"1","key":"1445_CR55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","volume":"70","author":"J Wolf","year":"2014","unstructured":"Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70(1):11\u201320.","journal-title":"Cytokine"},{"issue":"5","key":"1445_CR56","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","volume":"26","author":"F Schaper","year":"2015","unstructured":"Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth F R. 2015;26(5):475\u201387.","journal-title":"Cytokine Growth F R"},{"issue":"2","key":"1445_CR57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/bst0270211","volume":"27","author":"J M\u00fcllberg","year":"1999","unstructured":"M\u00fcllberg J, Vollmer P, Althoff K, M\u00e4rz P, Rose-John S. Generation and function of the soluble interleukin-6 receptor. Biochem Soc Trans. 1999;27(2):211\u20139.","journal-title":"Biochem Soc Trans."},{"key":"1445_CR58","doi-asserted-by":"crossref","first-page":"25550","DOI":"10.1038\/srep25550","volume":"6","author":"S Riethmueller","year":"2016","unstructured":"Riethmueller S, Ehlers JC, Lokau J, D\u00fcsterh\u00f6ft S, Knittler K, Dombrowsky G, et al. Cleavage site localization differentially controls interleukin-6 receptor proteolysis by ADAM10 and ADAM17. Sci Rep. 2016;6:25550.","journal-title":"Sci Rep."},{"issue":"1","key":"1445_CR59","doi-asserted-by":"crossref","first-page":"e2000080","DOI":"10.1371\/journal.pbio.2000080","volume":"15","author":"S Riethmueller","year":"2017","unstructured":"Riethmueller S, Somasundaram P, Ehlers JC, Hung CW, Flynn CM, Lokau J, et al. Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation. PLoS Biol. 2017;15(1):e2000080.","journal-title":"PLoS Biol."},{"issue":"4","key":"1445_CR60","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cpt.782","volume":"102","author":"S Rose-John","year":"2017","unstructured":"Rose-John S. The soluble interleukin 6 receptor: advanced therapeutic options in inflammation. Clin Pharmacol Therap. 2017;102(4):591\u20138.","journal-title":"Clin Pharmacol Therap."},{"issue":"2","key":"1445_CR61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3000281","volume":"300","author":"S Rose-John","year":"1994","unstructured":"Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994;300(2):281\u201390.","journal-title":"Biochem J."},{"issue":"1","key":"1445_CR62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1432-1033.1990.tb15548.x","volume":"190","author":"S Rose-John","year":"1990","unstructured":"Rose-John S, Schooltink H, Lenz D, Hipp E, Dufhues G, Schmitz H, et al. Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Europ J Biochem. 1990;190(1):79\u201383.","journal-title":"Europ J Biochem."},{"issue":"4","key":"1445_CR63","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/intimm\/dxh396","volume":"18","author":"HH Oberg","year":"2006","unstructured":"Oberg HH, Wesch D, Gr\u00fcssel S, Rose-John S, Kabelitz D. Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+ CD25\u2212 and CD25high regulatory T cells. Int Immunol. 2006;18(4):555\u201363.","journal-title":"Int Immunol."},{"issue":"1","key":"1445_CR64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.smim.2013.11.002","volume":"26","author":"J Scheller","year":"2014","unstructured":"Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Sem Immunol. 2014;26(1):2\u201312.","journal-title":"Sem Immunol."},{"issue":"6","key":"1445_CR65","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/CCM.0b013e318211ff56","volume":"39","author":"T Barkhausen","year":"2011","unstructured":"Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg RP, Dorsch M, et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011;39(6):1407\u201313.","journal-title":"Crit Care Med."},{"issue":"6","key":"1445_CR66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/2040620716653745","volume":"7","author":"S Sarosiek","year":"2016","unstructured":"Sarosiek S, Shah R, Munshi NC. Review of siltuximab in the treatment of multicentric Castleman\u2019s disease. Ther Adv Hematol. 2016;7(6):360\u20136.","journal-title":"Ther Adv Hematol."},{"key":"1445_CR67","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-pharmtox-010611-134715","volume":"52","author":"T Tanaka","year":"2012","unstructured":"Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012;52:199\u2013219.","journal-title":"Annu Rev Pharmacol Toxicol."},{"issue":"20","key":"1445_CR68","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970\u20135.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7","key":"1445_CR69","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","volume":"92","author":"P Luo","year":"2020","unstructured":"Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814\u20138.","journal-title":"J Med Virol."},{"issue":"5","key":"1445_CR70","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2020-217442","volume":"79","author":"C Mihai","year":"2020","unstructured":"Mihai C, Dobrota R, Schr\u00f6der M, Garaiman A, Jordan S, Becker MO, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis. 2020;79(5):668\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"1445_CR71","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/ajt.15935","volume":"20","author":"F Fontana","year":"2020","unstructured":"Fontana F, Alfano G, Mori G, Amurri A, Tei L, Ballestri M, et al. Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine. Am J Transp. 2020;20(7):1902\u20136.","journal-title":"Am J Transp."},{"issue":"6","key":"1445_CR72","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40261-020-00917-3","volume":"40","author":"S Zhang","year":"2020","unstructured":"Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clini Drug Invest. 2020;40(6):511\u20138.","journal-title":"Clini Drug Invest."},{"issue":"6","key":"1445_CR73","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.autrev.2016.02.012","volume":"15","author":"Y Ferfar","year":"2016","unstructured":"Ferfar Y, Mirault T, Desbois AC, Comarmond C, Messas E, Savey L, et al. Biotherapies in large vessel vasculitis. Autoimm Rev. 2016;15(6):544\u201351.","journal-title":"Autoimm Rev."},{"key":"1445_CR74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejim.2018.06.008","volume":"57","author":"M Samson","year":"2018","unstructured":"Samson M, Devilliers H, Ly KH, Maurier F, Bienvenu B, Terrier B, et al. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: a prospective study. Europ J Int Med. 2018;57:96\u2013104.","journal-title":"Europ J Int Med."},{"key":"1445_CR75","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4137\/CMAMD.S4864","volume":"3","author":"G Jones","year":"2010","unstructured":"Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81\u20139.","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord."},{"issue":"2","key":"1445_CR76","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4049\/jimmunol.1201044","volume":"190","author":"J Hoge","year":"2013","unstructured":"Hoge J, Yan I, J\u00e4nner N, Schumacher V, Chalaris A, Steinmetz OM, et al. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol. 2013;190(2):703\u201311.","journal-title":"J Immunol."},{"issue":"9","key":"1445_CR77","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.4049\/jimmunol.1102137","volume":"188","author":"CM Wunderlich","year":"2012","unstructured":"Wunderlich CM, Deli\u0107 D, Behnke K, Meryk A, Str\u00f6hle P, Chaurasia B, et al. Cutting edge: Inhibition of IL-6 trans-signaling protects from malaria-induced lethality in mice. J Immunol. 2012;188(9):4141\u20134.","journal-title":"J Immunol."},{"issue":"5","key":"1445_CR78","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","volume":"1813","author":"J Scheller","year":"2011","unstructured":"Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878\u201388.","journal-title":"Biochim Biophys Acta."},{"issue":"5","key":"1445_CR79","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/1078-0432.CCR-14-1678","volume":"21","author":"A Deisseroth","year":"2015","unstructured":"Deisseroth A, Ko CW, Nie L, Zirkelbach JF, Zhao L, Bullock J, et al. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res. 2015;21(5):950\u20134.","journal-title":"Clin Cancer Res."},{"key":"1445_CR80","unstructured":"European Medicines Agency. Summary of product characteristics of siltuximab. Agencia Espa\u00f1ola de Medicamentos Y Productos Sanitarios, Available: https:\/\/cima.aemps.es\/cima\/pdfs\/ft\/114928001\/FT_114928001.pdf. 2019"},{"key":"1445_CR81","unstructured":"Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. MedRxiv. 2020."},{"issue":"3","key":"1445_CR82","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S2352-3026(19)30257-1","volume":"7","author":"F van Rhee","year":"2020","unstructured":"van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020;7(3):209\u201317.","journal-title":"Lancet Haematol."},{"issue":"9","key":"1445_CR83","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s00296-012-2423-3","volume":"32","author":"S Kim","year":"2012","unstructured":"Kim S, \u00d6st\u00f6r AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol int. 2012;32(9):2601\u20134.","journal-title":"Rheumatol int."},{"issue":"19","key":"1445_CR84","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","volume":"21","author":"C Casper","year":"2015","unstructured":"Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, et al. Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease. Clin Cancer Res. 2015;21(19):4294\u2013304.","journal-title":"Clin Cancer Res."},{"key":"1445_CR85","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3389\/fimmu.2019.02629","volume":"10","author":"M Bloomfield","year":"2019","unstructured":"Bloomfield M, Parackova Z, Cabelova T, Pospisilova I, Kabicek P, Houstkova H, et al. Anti-IL6 autoantibodies in an infant with CRP-less septic shock. Front Immunol. 2019;10:2629.","journal-title":"Front Immunol."},{"key":"1445_CR86","doi-asserted-by":"crossref","unstructured":"Benucci M, Giannasi G, Cecchini P, Gobbi FL, Damiani A, Grossi V, et al. COVID\u201019 pneumonia treated with Sarilumab: a clinical series of eight patients. J Med Virol. 2020;1\u20133.","DOI":"10.1002\/jmv.26062"},{"issue":"5","key":"1445_CR87","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1159\/000495897","volume":"51","author":"SF Li","year":"2018","unstructured":"Li SF, Gong MJ, Zhao FR, Shao JJ, Xie YL, Zhang YG, et al. Type I interferons: distinct biological activities and current applications for viral infection. Cell Physiol Biochem. 2018;51(5):2377\u201396.","journal-title":"Cell Physiol Biochem."},{"issue":"4","key":"1445_CR88","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","volume":"25","author":"FC Lin","year":"2014","unstructured":"Lin FC, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine Growth F R. 2014;25(4):369\u201376.","journal-title":"Cytokine Growth F R"},{"issue":"11","key":"1445_CR89","doi-asserted-by":"crossref","first-page":"21045","DOI":"10.3390\/ijms151121045","volume":"15","author":"H Zhou","year":"2014","unstructured":"Zhou H, Chen S, Wang M, Cheng A. Interferons and their receptors in birds: a comparison of gene structure, phylogenetic analysis, and cross modulation. Int J Mol Sci. 2014;15(11):21045\u201368.","journal-title":"Int J Mol Sci."},{"issue":"5","key":"1445_CR90","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375\u201386.","journal-title":"Nat Rev Immunol."},{"issue":"6121","key":"1445_CR91","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339(6121):786\u201391.","journal-title":"Science"},{"key":"1445_CR92","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","volume":"9","author":"AJ Lee","year":"2018","unstructured":"Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018;9:2061.","journal-title":"Front Immunol."},{"issue":"1","key":"1445_CR93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cellimm.2011.03.007","volume":"269","author":"N Gill","year":"2011","unstructured":"Gill N, Chenoweth MJ, Verdu EF, Ashkar AA. NK cells require type I IFN receptor for antiviral responses during genital HSV-2 infection. Cell Immunol. 2011;269(1):29\u201337.","journal-title":"Cell Immunol."},{"key":"1445_CR94","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3389\/fimmu.2016.00694","volume":"7","author":"D Gotthardt","year":"2017","unstructured":"Gotthardt D, Sexl V. STATs in NK-cells: the good, the bad, and the ugly. Front Immunol. 2017;7:694.","journal-title":"Front Immunol."},{"key":"1445_CR95","doi-asserted-by":"crossref","unstructured":"NanY, Wu C, Zhang YJ. Interferon independent non-canonical STAT Activation and virus induced inflammation. Viruses. 2018;10(4):196.","DOI":"10.3390\/v10040196"},{"key":"1445_CR96","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cytogfr.2018.02.002","volume":"40","author":"K Sutter","year":"2018","unstructured":"Sutter K, Dickow J, Dittmer U. Interferon \u03b1 subtypes in HIV infection. Cytokine Growth F R. 2018;40:13\u20138.","journal-title":"Cytokine Growth F R"},{"issue":"6","key":"1445_CR97","doi-asserted-by":"crossref","first-page":"e00696","DOI":"10.1002\/brb3.696","volume":"7","author":"C Madsen","year":"2017","unstructured":"Madsen C. The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis. Brain Behav. 2017;7(6):e00696.","journal-title":"Brain Behav."},{"issue":"24","key":"1445_CR98","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1001\/jama.290.24.3222","volume":"290","author":"MR Loutfy","year":"2003","unstructured":"Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003;290(24):3222\u20138.","journal-title":"JAMA"},{"issue":"2","key":"1445_CR99","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000098242","volume":"50","author":"C Scagnolari","year":"2007","unstructured":"Scagnolari C, Trombetti S, Alberelli A, Cicetti S, Bellarosa D, Longo R, et al. The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced; proteins. Intervirol. 2007;50(2):156\u201360.","journal-title":"Intervirol."},{"key":"1445_CR100","doi-asserted-by":"crossref","unstructured":"Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, Florence AD. Type 1 interferons as a potential treatment against COVID-19.\u00a0Antiviral Res. 2020;104791.","DOI":"10.1016\/j.antiviral.2020.104791"},{"key":"1445_CR101","unstructured":"Arabi YM, Shalhoub S, Al Omari A, Mandourah Y, Al-Hameed F, Sindi A, et al. Effect of ribavirin and interferon on the outcome of critically ill patients with MERS. In C63. VIiral Resp Infect. 2017;6067\u20136067."},{"issue":"1","key":"1445_CR102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Leist SR, Sch\u00e4fer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Comm. 2020;11(1):1\u20134.","journal-title":"Nature Comm."},{"issue":"8","key":"1445_CR103","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1099\/jmm.0.05320-0","volume":"52","author":"Z Zhao","year":"2003","unstructured":"Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou. PR China J Med Microbial. 2003;52(8):715\u201320.","journal-title":"PR China J Med Microbial."},{"issue":"11","key":"1445_CR104","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","volume":"14","author":"AS Omrani","year":"2014","unstructured":"Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090\u20135.","journal-title":"Lancet Infect Dis."},{"issue":"18","key":"1445_CR105","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1074\/jbc.R116.774562","volume":"292","author":"G Schreiber","year":"2017","unstructured":"Schreiber G. The molecular basis for differential type I interferon signaling. J Biol Chem. 2017;292(18):7285\u201394.","journal-title":"J Biol Chem."},{"issue":"10","key":"1445_CR106","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2006.10.038","volume":"25","author":"CM James","year":"2007","unstructured":"James CM, Abdad MY, Mansfield JP, Jacobsen HK, Vind AR, Stumbles PA, et al. Differential activities of alpha\/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine. 2007;25(10):1856\u201367.","journal-title":"Vaccine."},{"issue":"6","key":"1445_CR107","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/135965350400900618","volume":"9","author":"C Scagnolari","year":"2004","unstructured":"Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9(6):1003\u201311.","journal-title":"Antivir Ther."},{"issue":"6","key":"1445_CR108","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","volume":"67","author":"JF Chan","year":"2013","unstructured":"Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606\u201316.","journal-title":"J Infect."},{"issue":"1","key":"1445_CR109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Therap. 2020;14(1):58\u201360.","journal-title":"Drug Discov Therap."},{"issue":"2","key":"1445_CR110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S2213-2600(13)70259-5","volume":"2","author":"G Bellingan","year":"2014","unstructured":"Bellingan G, Maksimow M, Howell DC, Stotz M, Beale R, Beatty M, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Resp Med. 2014;2(2):98\u2013107.","journal-title":"Lancet Resp Med."},{"key":"1445_CR111","unstructured":"Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD. SARS-CoV-2 is sensitive to type I interferon pretreatment. BioRxi.2020."},{"issue":"2","key":"1445_CR112","first-page":"51","volume":"4","author":"P Payandemehr","year":"2020","unstructured":"Payandemehr P, Azhdarzadeh M, Bahrami-Motlagh H, Hadadi A, Najmeddin F, Shahmirzaei S, et al. Interferon beta-1a as a candidate for COVID-19 treatment; an open-label single-arm clinical trial. Adv J Emerg Med. 2020;4(2):51\u201351.","journal-title":"Adv J Emerg Med."},{"key":"1445_CR113","doi-asserted-by":"crossref","unstructured":"Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129(9).","DOI":"10.1172\/JCI126363"},{"issue":"6","key":"1445_CR114","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000508247","volume":"181","author":"F Seif","year":"2020","unstructured":"Seif F, Aazami H, Khoshmirsafa M, Kamali M, Mohsenzadegan M, Pornour M, et al. JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol. 2020;181(6):467\u201375.","journal-title":"Int Arch Allergy Immunol."},{"issue":"8","key":"1445_CR115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","volume":"41","author":"W Luo","year":"2020","unstructured":"Luo W, Li YX, Jiang LJ, Chen Q, Wang T, Ye DW. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacolog Sci. 2020;41(8):531\u201343.","journal-title":"Trends Pharmacolog Sci."},{"key":"1445_CR116","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/TCRM.S192440","volume":"15","author":"P Kawalec","year":"2019","unstructured":"Kawalec P, \u015aladowska K, Malinowska-Lipie\u0144 I, Brzostek T, K\u00f3zka M. New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib. Ther Clin Risk Manag. 2019;15:275.","journal-title":"Ther Clin Risk Manag."},{"issue":"1","key":"1445_CR117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.virusres.2007.02.014","volume":"133","author":"MJ Cameron","year":"2008","unstructured":"Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008;133(1):13\u20139.","journal-title":"Virus Res"},{"key":"1445_CR118","first-page":"1022","volume":"14","author":"B Russell","year":"2020","unstructured":"Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19\u2014a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022.","journal-title":"Ecancermedicalscience."},{"key":"1445_CR119","unstructured":"European Medicines Agency. Olumiant (baricitinib). 2019; https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant"},{"issue":"10223","key":"1445_CR120","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30.","journal-title":"Lancet"},{"key":"1445_CR121","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-020-0451-z","volume":"16","author":"G Schett","year":"2020","unstructured":"Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nature Rev Rheumatol. 2020;16:465\u201370.","journal-title":"Nature Rev Rheumatol."},{"issue":"4","key":"1445_CR122","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400\u20132.","journal-title":"Lancet Infect Dis."},{"issue":"7","key":"1445_CR123","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GA Sanchez","year":"2018","unstructured":"Sanchez GA, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041\u201352.","journal-title":"J Clin Invest."},{"issue":"4","key":"1445_CR124","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5114\/reum.2019.87609","volume":"57","author":"M Madej","year":"2019","unstructured":"Madej M, Woytala P, Frankowski M, Lubi\u0144ski \u0141, Sokolik R, Sebastian A, et al. Tofacitinib in the treatment of active rheumatoid arthritis\u2013single-centre experience. Reumatologia. 2019;57(4):192.","journal-title":"Reumatologia."},{"issue":"1","key":"1445_CR125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016;46(1):71\u201380.","journal-title":"Semin Arthritis Rheum."},{"key":"1445_CR126","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00728-18","author":"Y Ma","year":"2018","unstructured":"Ma Y, Wang C, Xue M, Fu F, Zhang X, Li L, et al. Coronavirus TGEV evades the type I interferon response through IRE1\u03b1-mediated manipulation of the miR-30a-5p\/SOCS1\/3 Axis. J Virol. 2018. https:\/\/doi.org\/10.1128\/JVI.00728-18.","journal-title":"J Virol."},{"issue":"1","key":"1445_CR127","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2050-7771-1-5","volume":"1","author":"M Furqan","year":"2013","unstructured":"Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res. 2013;1(1):5.","journal-title":"Biomarker Res."},{"issue":"1","key":"1445_CR128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","volume":"146","author":"Y Cao","year":"2020","unstructured":"Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146(1):137-146.e3.","journal-title":"J Allergy Clin Immunol."},{"key":"1445_CR129","doi-asserted-by":"crossref","unstructured":"Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020;21:2272.","DOI":"10.3390\/ijms21072272"},{"key":"1445_CR130","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/eji.202048723","volume":"50","author":"K Subbarao","year":"2020","unstructured":"Subbarao K, Mordant F, Rudraraju R. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience. Eur J Immunol. 2020;50:1447\u201353.","journal-title":"Eur J Immunol."},{"key":"1445_CR131","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","volume":"211","author":"J Mair-Jenkins","year":"2015","unstructured":"Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80\u201390.","journal-title":"J Infect Dis."},{"key":"1445_CR132","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","volume":"35","author":"JY Ahn","year":"2020","unstructured":"Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, Jeong SJ, Kim JH, Ku NS, Yeom JS, Roh J. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35:e149.","journal-title":"J Korean Med Sci."},{"issue":"16","key":"1445_CR133","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582\u20139.","journal-title":"JAMA"},{"issue":"11","key":"1445_CR134","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","volume":"26","author":"ST Liu","year":"2020","unstructured":"Liu ST, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, Sanky C. Convalescent plasma treatment of severe COVID-19: a propensity score\u2013matched control study. Nat Med. 2020;26(11):1708\u201313.","journal-title":"Nat Med."}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-021-01445-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00011-021-01445-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-021-01445-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T15:02:22Z","timestamp":1697900542000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00011-021-01445-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":134,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1007\/s00011-021-01445-2","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"21 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}